About Us

ADispell is a technology development company focused on creating solutions that address Alzheimer’s Disease and other neurodegenerative disorders. The company business model starts with licensing-in technology then performing the early and middle stage pharmaceutical development work. ADispell then will consider licensing the technology or continuing the development process into clinical trials.